Somerville, Mass., September 17, 2025 – Generate:Biomedicines today announced the appointment of Laurie Lee, MD, as Chief Medical Officer for its Immunology & Inflammation (I&I) portfolio. A board-certified physician in both Pediatrics and Allergy and Immunology, Dr. Lee brings more than 17 years of industry experience leading late-stage clinical development programs through regulatory approvals. Her appointment strengthens the company’s I&I clinical leadership as it advances novel protein therapeutics through clinical trials.
“Laurie’s deep medical expertise and proven track record in I&I drug development make her ideally suited to lead our clinical strategy in this critical therapeutic area,” said Mike Nally, Chief Executive Officer of Generate:Biomedicines. “Her experience bringing complex therapies from Phase 2 through regulatory approval will be instrumental as we advance our I&I pipeline and deliver on our platform’s potential to benefit patients with immune and inflammatory diseases.”
Dr. Lee joins Generate:Biomedicines from CSL Behring, where she most recently served as Vice President of Research and Development, Transplant and Immunology, leading global clinical development programs. During her tenure, she led the largest placebo-controlled study in antibody-mediated rejection following kidney transplant, as well as corporate strategy for several therapeutic areas. Dr. Lee also developed novel patient recruitment and regulatory strategies to support the advancement of late-stage clinical development programs.
Previously, she progressed through multiple leadership roles over more than a decade at GlaxoSmithKline, including serving as Vice President, Medicine Development Leader, where she guided respiratory and allergy candidates through late-stage development and led the Trelegy Ellipta asthma program through regulatory submissions. Dr. Lee also played a key role in the design and execution of numerous Phase 2, 3, and 4 studies, primarily in respiratory and allergy and including a large pediatric safety trial in asthma, while advising on rare diseases and serving as a reviewer and committee chair for respiratory drug development. Dr. Lee also served as a faculty member in pediatrics at Duke University Medical Center for more than a decade, where she conducted research on primary immune deficiency syndromes and bone marrow transplantation in the neonatal period.
About Generate:Biomedicines
Generate:Biomedicines is a technology company founded at the intersection of machine learning, biological engineering, and medicine that is advancing a new era of programmable biology to engineer better medicines for patients, faster. The Generate Platform’s infusion of technology into biology allows us to address historically undruggable and hard-to-drug targets as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded by Flagship Pioneering in 2018, Generate is a clinical-stage company leading a fundamental shift from drug discovery to drug generation. Learn more at www.generatebiomedicines.com or follow us on X, LinkedIn, and YouTube.
Generate Media Contact
Megan McLaughlin, Media Relations
Email: pr@generatebiomedicines.com